Liquid Biopsy Monitoring Of EGFR T790M in Advanced Non-Small Cell Lung Cancer

Brief summary (registry, in English)

The goal of this retrospective observational study is to assess the clinical utility of plasma-based EGFR testing for detection and longitudinal monitoring of the acquired T790M resistance mutation in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with first- or second-generation EGFR tyrosine kinase inhibitors in routine clinical practice in Tunisia. The main questions it aims to answer are: * What is the detection rate of EGFR T790M mutation in plasma at the time of disease progression? * Does repeated liquid biopsy increase the cumulative detection of T790M? * Is T790M emergence associated with baseline clinical and molecular characteristics? * Is T790M status associated with progression-free survival? Participants underwent plasma sampling for circulating tumor DNA analysis during follow-up, and clinical and molecular data were retrospectively collected from medical records to evaluate mutation dynamics and outcomes.

What you commit to

• Study type: Observational
• Participants enrolled: 70
• From 1 Mar 2023 to the primary completion date, 30 Dec 2025
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.